Skip to content
OpenCapital
Get started

Bausch Health Companies BHC EV / EBITDA

EV / EBITDA at other companies

PBH
Prestige Consumer HealthcarePBH
11.1×-3.1×
Bausch + Lomb logo
Bausch + LombBLCO
16.1×-3.1×
Johnson & Johnson logo
Johnson & JohnsonJNJ
18.8×+4.2×
AbbVie logo
AbbVieABBV
19.8×—
Organon logo
OrganonOGN
8×-1.0×
HRO
HarrowHROW
70.8×-139×

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.79B-15.9%
Enterprise value$21.24B-5.6%
P/S0.2×0.0×

Profitability

See full
Gross margin71.4%—
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%—
Debt / equity45.2×—
Current ratio1.3×0.0×

Where this comes from

Calculated from Bausch Health Companies’s reported figures.

enterprise value/ebitda=12×

Based on the most recent quarter.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch Health Companies's EV / EBITDA?
Bausch Health Companies (BHC) reported EV / EBITDA of 12× in Q1 2026.
How has Bausch Health Companies's EV / EBITDA changed year-over-year?
Bausch Health Companies's EV / EBITDA increased by 47.7% year-over-year, from 8.1× to 12×.
What is the long-term trend for Bausch Health Companies's EV / EBITDA?
Over 5 years (2020 to 2025), Bausch Health Companies's EV / EBITDA has grown at a -10.0% compound annual growth rate (CAGR), from 12.5× to 7.4×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.